32results about How to "Early stage" patented technology

An object of the present invention is to provide a probe for imaging a β-sheet structure protein which can be used for the diagnosis of conformational diseases, particularly disease (tauopathy) having a cardinal symptom such as intracerebral accumulation of tau protein, for example, Alzheimer's disease. Another object of the present invention is to provide a compound which is highly specific to tau and can image tau with satisfactory sensitivity, and also has high brain transition, low or non-recognized bone-seeking properties and low or non-recognized toxicity.According to the present invention, the above problems are solved by providing a compound of a formula I (wherein A, R1, R2, R3, R4, R5, R6, Ra and Rb are as defined in the present description) or a pharmaceutically acceptable salt or solvate thereof.

A wafer for forming an imaging element has a test pattern and a plurality of imaging element units. The wafer has an imaging region which includes a great number of photoelectric conversion pixels, an imaging element units and a test pattern. The test pattern includes a testing organic photoelectric conversion film and a testing counter electrode having the same configuration and formed at the same time as the organic photoelectric conversion film and a counter electrode, respectively of the photoelectric conversion pixels. A first testing terminal is electrically connected to the undersurface side of the testing organic photoelectric conversion film, and a second testing terminal is electrically connected to the testing counter electrode. A protective film is formed over the entire semiconductor wafer so as to cover the imaging region and the test pattern, and is then partially removed so that a part of each testing terminal is exposed.

Method of detection or diagnosis of abnormal gene expression in an individual comprising determining in a sample from the individual the presence or absence of a chromosome structure in which two separate regions of the gene have been brought into close proximity, to thereby detect or diagnose whether the individual has abnormal gene expression.

Method of detection or diagnosis of abnormal gene expression in an individual comprising determining in a sample from the individual the presence or absence of a chromosome structure in which two separate regions of the gene have been brought into close proximity, to thereby detect or diagnose whether the individual has abnormal gene expression.

A system (40) for diagnosis and staging of early stages of cancer in the tissue of a patient is provided. The system—is configured to combine information from a Polarized Light Scattering Spectroscopy measurement (70) having a first probe depth, and a Differential Path Length Spectroscopy measurement (60) having a second probe depth, wherein the second probe depth is set larger than' the first probe depth. By comparing the results of the Polarized Light Scattering Spectroscopy and Differential Path Length Spectroscopy measurements early stages of cancer, such as dysplasia may be detected. Also hyperplasia, carcinoma in situ, and carcinoma may be detected. A computer-readable medium, method and use are also provided.

The present invention relates to a biomarker associated with a cancer and a method using the biomarker to evaluate a risk of proliferation, invasion, or metastasis of a cancer. The method of the present invention comprises the following steps: (A) providing a tissue sample to evaluate for risk of proliferation, invasion, or metastasis of a cancer, wherein the tissue sample comprises a non-cancer region, and a suspected cancer region; (B) detecting expression levels of a biomarker and a predetermined standard in the non-cancer region and the suspected cancer region respectively, wherein the biomarker is T-cell lymphoma invasion and metastasis 2 (TIAM2); (C) comparing the expression levels of the biomarker and the predetermined standard in the non-cancer region to the expression levels of the biomarker and the predetermined standard in the suspected cancer region.

A rapidly dehydrating fluid (RDF) composition that forms a permeable and decomposable plug and methods of lost circulation control and manufacture of the RDF composition. The RDF composition may include a carrier fluid such as water, a cellulosic microfiber viscosifier, date tree seed particles, and fibers formed from date tree waste such as date tree trunks. The RDF composition may mitigate or prevent lost circulation by forming a decomposable plug in a fracture of the lost circulation zone and may also enable the production of hydrocarbons from the zone without removal of the plug.